Neovasc Inc.
13700 Mayfield Place
Suite 2135
Richmond
British Columbia
V6V 2E4
Canada
Tel: 604-270-4344
Fax: 604-270-4384
Website: http://www.neovasc.com/
Email: info@neovasc.com
379 articles about Neovasc Inc.
-
Shockwave Medical Completes Acquisition of Neovasc - April 11, 2023
4/11/2023
Shockwave Medical, Inc. today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).
-
Shockwave Medical Completes Acquisition of Neovasc
4/11/2023
Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced the completion of its previously announced acquisition of Neovasc Inc..
-
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
3/31/2023
via NewMediaWire – Neovasc Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
-
Neovasc Shareholders Approve Acquisition by Shockwave Medical
3/6/2023
Neovasc Inc. is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the “Shares”) by Shockwave Medical, Inc.
-
Neovasc Announces German Reimbursement Renewal
2/1/2023
Neovasc, Inc. announced the German Institute for the Hospital Remuneration System has awarded the Neovasc Reducer™, a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.
-
Shockwave Medical to Acquire Neovasc
1/17/2023
Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN) announced today that the Company has entered into a binding agreement (the “Arrangement Agreement”) with Shockwave Medical, Inc. (“Shockwave”), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the “Common Shares”) of the Company (the “Transaction”).
-
Shockwave Medical Announces Agreement to Acquire Neovasc
1/17/2023
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina.
-
Neovasc Announces Progress on COSIRA-II Clinical Trial
11/28/2022
Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotal clinical trial the Company is executing for the Neovasc Reducer™ (“Reducer”) towards an approval decision for the device in the United States.
-
Neovasc Announces Third Quarter 2022 Financial Results and Provides Corporate Update
11/10/2022
Neovasc Inc. reported financial results for the third quarter ended September 30, 2022.
-
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
11/8/2022
Neovasc Inc. announced that the Centers for Medicare and Medicaid Services has assigned the Neovasc Reducer™ implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.
-
Neovasc to Report Third Quarter Financial Results on November 10, 2022
10/27/2022
Neovasc Inc. (NASDAQ , TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022.
-
Neovasc Provides Corporate Update Following Clinical Data Release
9/20/2022
Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference (“TCT”) held September 16-19 in Boston.
-
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
9/16/2022
Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.
-
Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina
9/15/2022
Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today commented on the Centers for Medicare and Medicaid Services (“CMS”) development of new codes for the diagnosis and tracking of refractory angina.
-
Neovasc Announces Key Events at TCT 2022
9/8/2022
Neovasc Inc. announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference, hosted by the Cardiovascular Research Foundation, taking place in person at the Boston Convention & Exhibition Center, September 16-19, 2022.
-
Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
8/30/2022
Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New York City.
-
Neovasc Announces Second Quarter 2022 Financial Results and Provides Corporate Update
8/11/2022
via NewMediaWire – Neovasc Inc. reported financial results for the second quarter ended June 30, 2022.
-
Neovasc to Report Second Quarter Financial Results on August 11, 2022
7/28/2022
Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022.
-
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
7/26/2022
Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”) Trial.
-
Neovasc Announces Direct Sales Operations in United Kingdom
7/5/2022
Expansion Driven by NICE Guidelines and Enhanced Reimbursement for the Neovasc Reduce r™.